Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials.
Dienstmann R, Garralda E, Aguilar S, Sala G, Viaplana C, Ruiz-Pace F, González-Zorelle J, Grazia LoGiacco D, Ogbah Z, Ramos Masdeu L, Mancuso F, Fasani R, Jimenez J, Martinez P, Oaknin A, Saura C, Oliveira M, Balmaña J, Carles J, Macarulla T, Elez E, Alsina M, Braña I, Felip E, Tabernero J, Rodon J, Nuciforo P, Vivancos A. Dienstmann R, et al. Among authors: aguilar s. JCO Precis Oncol. 2020 May 14;4:PO.19.00398. doi: 10.1200/PO.19.00398. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923891 Free PMC article.
ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
Verdaguer H, Saurí T, Acosta DA, Guardiola M, Sierra A, Hernando J, Nuciforo P, Miquel JM, Molero C, Peiró S, Serra-Camprubí Q, Villacampa G, Aguilar S, Vivancos A, Tabernero J, Dienstmann R, Macarulla T. Verdaguer H, et al. Among authors: aguilar s. Clin Cancer Res. 2022 Apr 14;28(8):1662-1671. doi: 10.1158/1078-0432.CCR-21-2384. Clin Cancer Res. 2022. PMID: 35042699
TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.
Puig I, Tenbaum SP, Chicote I, Arqués O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P, Seoane J, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG. Puig I, et al. Among authors: aguilar s. J Clin Invest. 2018 Aug 31;128(9):3887-3905. doi: 10.1172/JCI96393. Epub 2018 Aug 6. J Clin Invest. 2018. PMID: 29944140 Free PMC article.
Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits.
Moserle L, Pons R, Martínez-Lozano M, Jiménez-Valerio GA, Vidal A, Suárez C, Trilla E, Jiménez J, de Torres I, Carles J, Senserrich J, Aguilar S, Palomero L, Amadori A, Casanovas O. Moserle L, et al. Among authors: aguilar s. EMBO Mol Med. 2020 Dec 7;12(12):e11889. doi: 10.15252/emmm.201911889. Epub 2020 Nov 5. EMBO Mol Med. 2020. PMID: 33151035 Free PMC article.
β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.
Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramón y Cajal S, Schwartz S Jr, Vivancos A, Espín E, Rojas S, Baselga J, Tabernero J, Muñoz A, Palmer HG. Tenbaum SP, et al. Among authors: aguilar s. Nat Med. 2012 Jun;18(6):892-901. doi: 10.1038/nm.2772. Nat Med. 2012. PMID: 22610277 Free article.
Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer.
Aguilera Ó, González-Sancho JM, Zazo S, Rincón R, Fernández AF, Tapia O, Canals F, Morte B, Calvanese V, Orgaz JL, Niell N, Aguilar S, Freije JM, Graña O, Pisano DG, Borrero A, Martínez-Useros J, Jiménez B, Fraga MF, García-Foncillas J, López-Otín C, Lafarga M, Rojo F, Muñoz A. Aguilera Ó, et al. Among authors: aguilar s. Oncotarget. 2015 Mar 20;6(8):5903-17. doi: 10.18632/oncotarget.3464. Oncotarget. 2015. PMID: 25788273 Free PMC article.
Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2.
Ortiz-Zapater E, Peiró S, Roda O, Corominas JM, Aguilar S, Ampurdanés C, Real FX, Navarro P. Ortiz-Zapater E, et al. Among authors: aguilar s. Am J Pathol. 2007 May;170(5):1573-84. doi: 10.2353/ajpath.2007.060850. Am J Pathol. 2007. PMID: 17456763 Free PMC article.
177 results